Allspring Global Investments Holdings LLC Purchases 143,834 Shares of argenx SE (NASDAQ:ARGX)

Allspring Global Investments Holdings LLC increased its stake in argenx SE (NASDAQ:ARGX - Free Report) by 38,152.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 144,211 shares of the company's stock after acquiring an additional 143,834 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.24% of argenx worth $89,391,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Stifel Financial Corp raised its holdings in argenx by 15.3% in the third quarter. Stifel Financial Corp now owns 8,832 shares of the company's stock valued at $4,788,000 after buying an additional 1,170 shares during the period. FMR LLC raised its holdings in argenx by 35.9% in the third quarter. FMR LLC now owns 4,793,472 shares of the company's stock valued at $2,598,445,000 after buying an additional 1,265,486 shares during the period. Simplify Asset Management Inc. raised its holdings in argenx by 64.0% in the third quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company's stock valued at $1,311,000 after buying an additional 944 shares during the period. Ritholtz Wealth Management raised its holdings in argenx by 85.5% in the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock valued at $552,000 after buying an additional 414 shares during the period. Finally, Westfield Capital Management Co. LP purchased a new position in argenx in the third quarter valued at approximately $571,000. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Price Performance

argenx stock traded down $11.93 during midday trading on Friday, hitting $639.41. The company's stock had a trading volume of 266,806 shares, compared to its average volume of 282,116. The stock's 50-day moving average price is $639.59 and its 200-day moving average price is $582.32. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wedbush reiterated an "outperform" rating and set a $655.00 price objective on shares of argenx in a research note on Tuesday, December 3rd. Robert W. Baird lowered shares of argenx from an "outperform" rating to a "neutral" rating and lifted their price objective for the company from $515.00 to $650.00 in a research note on Friday, November 1st. JPMorgan Chase & Co. lifted their price objective on shares of argenx from $640.00 to $670.00 and gave the company an "overweight" rating in a research note on Monday, November 4th. Scotiabank upgraded shares of argenx from a "sector perform" rating to a "sector outperform" rating and lifted their price objective for the company from $439.00 to $715.00 in a research note on Tuesday, November 5th. Finally, HC Wainwright restated a "buy" rating and issued a $717.00 price target (up previously from $670.00) on shares of argenx in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $658.39.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.